Answers are grounded in this paper and cite their sources.
This study evaluates the disease burden, treatment patterns, and healthcare resource utilization among patients with ulcerative colitis (UC) from Dubai, United Arab Emirates. The study was conducted from January 1, 2014, to September 30, 2023, using the Dubai Real-world e-claims database. The initial observed diagnosis of UC, whether principal, secondary, or occurring upon hospital admission, was termed the index diagnosis date. The timeframe spanning from January 1, 2014, to September 30, 2022, was referred to as the index period. Patients with a first observed diagnosis claim for UC any time during the index period were analyzed overall and by treatment cohort. Cohort 1 comprised patients treated with conventional therapies like corticosteroids, immunomodulators, and 5-aminosalicylic acid (5-ASA). Cohort 2 included patients whose ongoing treatment regimen involved advanced options, such as biologics and targeted synthetic small molecules. The study included 11,812 patients (median age: 38 years). Among 5618 patients with available sex data, 61.9% were male and 38.1% were female. The annual claims-based proportion of prevalent patients with UC ranged from 0.07% to 0.10% from 2014 to 2022, with no consistent year-over-year increase. Reported comorbidities included immune-mediated disorders (25.6%), psychological disorders (4.8%), and other comorbidities (34.8%). 5-ASA (91.6%) and corticosteroids (33.6%) were commonly prescribed, followed by biologics (6.9%). In the overall cohort, the median all-cause and disease-specific costs incurred were USD 2703.40 and USD 1314.70, respectively. The median disease-specific costs incurred for immune-mediated disorders, psychological disorders, and other comorbidities were USD 407.10, USD 333.10, and USD 461.40, respectively, during the 12-month post-index period. The study cohort reported a high disease burden, frequent comorbidities, and significant healthcare costs. Most patients were treated primarily with conventional therapies such as 5-ASA and corticosteroids, while newer treatments such as biologics were used as advanced therapies. Additional research is needed to assess whether biologics and newer treatments reduce the disease burden of UC in Dubai.
No takes yet. Share an insight, caveat, or question.
Awadhi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: